Next Generation News and Research

RSS

Recent advances in CAR-NK cell therapy could revolutionze cancer treatment

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.

8 Jan 2026

In Lodge Grass, Montana, a Crow community works to rebuild from meth’s destruction

Brothers Lonny and Teyon Fritzler walked amid the tall grass and cottonwood trees surrounding their boarded-up childhood home near the Little Bighorn River and daydreamed about ways to rebuild.

8 Jan 2026

New DNA tests reveal hidden biological traces on Renaissance art

DNA analysis of cultural artifacts shows diverse biological profiles, but contamination and mixed signals complicate historical lineage interpretation.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Spleen-driven immune tolerance may protect transplanted organs

New research from the University of Minnesota Medical School offers a new view of how the immune system responds to organ transplants.

7 Jan 2026

New antibody mechanisms disrupt bacterial adhesion in urinary tract infections

Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines of attack is to cling tenaciously to the surfaces of targeted human cells.

7 Jan 2026

Pain-sensing neurons in the gut spark inflammatory immune responses

Pain sensing neurons in the gut kindle inflammatory immune responses that cause allergies and asthma, according to a new study by Weill Cornell Medicine.

7 Jan 2026

MD Anderson and SOPHiA GENETICS join forces to accelerate data-driven cancer care

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

7 Jan 2026

New $8.5 million renewal grant fuels research on children's heart health

The National Institutes of Health has awarded the Icahn School of Medicine at Mount Sinai an $8.5 million renewal grant to continue groundbreaking work aimed at understanding and improving long-term outcomes for children with congenital heart disease-the most common type of birth defect in the United States.

7 Jan 2026

Nuclera eProtein Discovery System installed at leading universities in Taiwan

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has completed the first installations of eProtein Discovery in Asia, with systems now operational at the Department of Pharmacy and the Department of Chemistry at the National Taiwan University (NTU) College of Medicine and the Center for Bioscience and Biotechnology and Department of Chemical Engineering at the National Cheng Kung University (NCKU).

7 Jan 2026

New therapeutic approach converts immune cells inside tumors into anticancer cell therapies

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor.

2 Jan 2026

Epigenetic clocks accurately predict age from human skeletal muscle

A new research paper was published in Volume 17, Issue 11 of Aging-US on November 26, 2025, titled "Epigenetic aging signatures and age prediction in human skeletal muscle."

30 Dec 2025

Aptamer Group and Alphazyme execute licensing agreement for synthetic aptamer-based enzyme modulation in hot-start PCR

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company specializing in enzymes for molecular biology, have executed a licensing agreement for a proprietary Optimer® binder developed for hot-start polymerase chain reaction (PCR) applications.

From Aptamer Group 24 Dec 2025